Raltegravir: an integrase inhibitor for HIV-1

Author： Evering Teresa H Markowitz Martin

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.17, Iss.3, 2008-03, pp. : 413-422

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection

By Anker Mary Corales Roberto B

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 1, 2008-01 ,pp. : 97-103

Informa Healthcare

Access to resources Recommend Favorite

Diketoacid Inhibitors of HIV-1 Integrase: From L-708,906 to Raltegravir and Beyond

Current Medicinal Chemistry, Vol. 19, Iss. 8, 2012-03 ,pp. : 1177-1192

Bentham Science Publishers

Access to resources Recommend Favorite

Elvitegravir: a once-daily inhibitor of HIV-1 integrase

By Wills Todd Vega Vivian

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 3, 2012-03 ,pp. : 395-401

Informa Healthcare

Access to resources Recommend Favorite

Synthesis of styrylbenzofuran derivatives as styrylquinoline analogues for HIV-1 integrase inhibitor

By Yoo H. Lee J.Y. Park J.H. Chung B.Y. Lee Y.S.

Il Farmaco, Vol. 58, Iss. 12, 2003-12 ,pp. : 1243-1250

Elsevier

Access to resources Recommend Favorite

Novel integrase inhibitor promising in triple-class resistant HIV-1

Inpharma, Vol. 1, Iss. 1560, 2006-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite